

# Matteo Santoni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1120416/publications.pdf>

Version: 2024-02-01

276  
papers

7,361  
citations

57681

46  
h-index

111975

67  
g-index

282  
all docs

282  
docs citations

282  
times ranked

10963  
citing authors

#	ARTICLE	IF	CITATIONS
1	Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis. <i>Tumori</i> , 2023, 109, 157-163.	0.6	1
2	Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. <i>European Urology Focus</i> , 2022, 8, 514-521.	1.6	64
3	Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 45-51.	0.7	6
4	A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. <i>Anti-Cancer Drugs</i> , 2022, 33, e43-e51.	0.7	2
5	Microbiota and prostate cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 1058-1065.	4.3	23
6	The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment. <i>Biomolecules</i> , 2022, 12, 107.	1.8	4
7	Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. <i>Future Oncology</i> , 2022, 18, 739-748.	1.1	11
8	Functional In Vitro Assessment of VEGFA/NOTCH2 Signaling Pathway and pRB Proteasomal Degradation and the Clinical Relevance of Mucolipin TRPML2 Overexpression in Glioblastoma Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 688.	1.8	3
9	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103596.	2.0	76
10	Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1038.	1.0	3
11	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. <i>European Urology Focus</i> , 2022, 8, 1696-1702.	1.6	17
12	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 285-295.	0.9	5
13	PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?. <i>Cancers</i> , 2022, 14, 907.	1.7	8
14	Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study. <i>European Urology</i> , 2022, 81, 623-624.	0.9	3
15	Chronic Cancer Pain: Opioids within Tumor Microenvironment Affect Neuroinflammation, Tumor and Pain Evolution. <i>Cancers</i> , 2022, 14, 2253.	1.7	17
16	Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 482-487.	0.9	3
17	Time-of-day infusion of immunotherapy in metastatic urothelial cancer (mUC): Should it be considered to improve survival outcomes?. <i>Journal of Clinical Oncology</i> , 2022, 40, e16541-e16541.	0.8	4
18	The prognostic role of nephrectomy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score: Subanalysis of the Meet-URO 15 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4535-4535.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103731.	2.0	9
20	Does timing of Immune checkpoint inhibitors (ICIs) administration in first line Metastatic Renal Cell Carcinoma (mRCC) have impact in survival outcomes?. <i>Journal of Clinical Oncology</i> , 2022, 40, e16512-e16512.	0.8	1
21	Coexpression of TRPML1 and TRPML2 Mucoipin Channels Affects the Survival of Glioblastoma Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7741.	1.8	3
22	Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2022, 172, 191-198.	1.3	8
23	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e84-e91.	0.9	23
24	Gut microbiota, immunity and pain. <i>Immunology Letters</i> , 2021, 229, 44-47.	1.1	20
25	Predicting future cancer burden in the United States by artificial neural networks. <i>Future Oncology</i> , 2021, 17, 159-168.	1.1	8
26	Treating Prostate Cancer by Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1551.	1.8	38
27	An update on investigational therapies that target STAT3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 245-251.	1.9	13
28	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. <i>Translational Andrology and Urology</i> , 2021, 10, 1562-1568.	0.6	2
29	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. <i>Translational Andrology and Urology</i> , 2021, 10, 1530-1540.	0.6	10
30	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like? a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1541-1552.	0.6	6
31	Agent-Based Learning Model for the Obesity Paradox in RCC. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 642760.	2.0	4
32	Knock-Down of Mucoipin 1 Channel Promotes Tumor Progression and Invasion in Human Glioblastoma Cell Lines. <i>Frontiers in Oncology</i> , 2021, 11, 578928.	1.3	8
33	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5522.	1.8	12
34	Impact of clinicopathological features on survival in patients treated with immune-based combinations for metastatic urothelial carcinoma: A meta-analysis of randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16534-e16534.	0.8	0
35	An update on immunotherapy in uro-oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 229-233.	0.4	2
36	Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. <i>Immunotherapy</i> , 2021, 13, 783-793.	1.0	3

#	ARTICLE	IF	CITATIONS
37	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , 2021, 26, 740-750.	1.9	19
38	The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6237.	1.8	15
39	Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. <i>European Urology</i> , 2021, 79, 887-889.	0.9	3
40	Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. <i>Pathology Research and Practice</i> , 2021, 222, 153440.	1.0	10
41	Quality of life assessment in renal cell carcinoma—Phase II and III clinical trials published between 2010 and 2020: a systematic review. <i>Future Oncology</i> , 2021, 17, 2671-2681.	1.1	17
42	Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. <i>Cancers</i> , 2021, 13, 3492.	1.7	3
43	Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation. <i>Cancers</i> , 2021, 13, 3471.	1.7	9
44	ERK Phosphorylation Regulates the Aml1/Runx1 Splice Variants and the TRP Channels Expression during the Differentiation of Glioma Stem Cell Lines. <i>Cells</i> , 2021, 10, 2052.	1.8	7
45	Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1237-1243.	1.5	12
46	Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1029-1054.	1.1	11
47	Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188547.	3.3	15
48	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021, 16, 625-632.	1.7	6
49	An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-14.	0.9	2
50	Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 154, 120-127.	1.3	71
51	The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors. <i>Diagnostics</i> , 2021, 11, 206.	1.3	15
52	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , 2021, 11, 138.	1.3	13
53	Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution. <i>Journal of Clinical Medicine</i> , 2021, 10, 5246.	1.0	2
54	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13519.	1.8	13

#	ARTICLE	IF	CITATIONS
55	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1455-1466.	1.5	7
56	The TRPV2 cation channels: from urothelial cancer invasiveness to glioblastoma multiforme interactome signature. <i>Laboratory Investigation</i> , 2020, 100, 186-198.	1.7	30
57	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 207-217.	1.5	5
58	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 141-150.	1.5	14
59	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	1.7	22
60	Designing novel immunocombinations in metastatic renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 1257-1268.	1.0	6
61	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020, 15, 495-501.	1.7	28
62	Exploring treatment with Ribociclib alone or in sequence/combo with Everolimus in ER+HER2 <sup>+</sup> Rb wild-type and knock-down in breast cancer cell lines. <i>BMC Cancer</i> , 2020, 20, 1119.	1.1	5
63	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020, 9, 2051.	1.8	65
64	Exploring the Spectrum of Kidney Ciliopathies. <i>Diagnostics</i> , 2020, 10, 1099.	1.3	8
65	Involvement of the TRPML Mucolipin Channels in Viral Infections and Anti-viral Innate Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 739.	2.2	30
66	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 491-501.	1.1	14
67	Emerging Role of Mucolipins TRPML Channels in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 659.	1.3	18
68	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020, 12, 1449.	1.7	72
69	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1950.	1.0	3
70	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , 2020, 9, 1495.	1.8	8
71	Renal Cell Carcinoma: genomic landscape and clinical implications. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 95-100.	0.4	1
72	Calcium Signaling and the Regulation of Chemosensitivity in Cancer Cells: Role of the Transient Receptor Potential Channels. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1131, 505-517.	0.8	28

#	ARTICLE	IF	CITATIONS
73	Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020, 21, 416-423.	1.0	6
74	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020, 21, 1463-1475.	1.0	10
75	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020, 21, 1664-1671.	1.0	12
76	Staging and Reporting of Renal Cell Carcinomas. , 2020, , 423-436.		0
77	Baseline and early change of neutrophil to lymphocyte ratio (bNLR and $\hat{I}$ NLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17081-e17081.	0.8	0
78	The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions. <i>Journal of Thoracic Disease</i> , 2020, 12, 7245-7256.	0.6	0
79	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS762-TPS762.	0.8	1
80	Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS596-TPS596.	0.8	0
81	BAP1 in solid tumors. <i>Future Oncology</i> , 2019, 15, 2151-2162.	1.1	20
82	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 141-152.	2.0	15
83	New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e871-e877.	0.9	28
84	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> 2019;75:111-118. <i>European Urology Oncology</i> , 2019, 2, 603-604.	2.6	1
85	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , 2019, 11, 1225.	1.7	15
86	Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications. <i>BioDrugs</i> , 2019, 33, 613-620.	2.2	23
87	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 147.	1.7	15
88	Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud MÃ©jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. <i>Eur Urol</i> 2018;74:842-843. <i>European Urology</i> , 2019, 75, e64-e66.	0.9	2
89	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721881537.	0.9	7
90	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019, 11, 830.	1.7	29

#	ARTICLE	IF	CITATIONS
91	The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes. <i>Targeted Oncology</i> , 2019, 14, 247-252.	1.7	17
92	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. <i>Frontiers in Oncology</i> , 2019, 9, 228.	1.3	20
93	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019, 11, 631-643.	1.0	38
94	Microbiome and Cancers, With Focus on Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 178.	1.3	20
95	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019, 39, 503-519.	1.1	26
96	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019, 11, 459.	1.7	38
97	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. <i>Cancers</i> , 2019, 11, 196.	1.7	23
98	Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S137-S137.	0.7	9
99	The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5683.	1.8	26
100	Transient Receptor Potential Cation Channels in Cancer Therapy. <i>Medical Sciences (Basel)</i> , 2019, 7, 100. <small>lock 10 Tf 50 382 Td</small>	1.3	27
101	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	0.6	3
102	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019, 8, 43.	1.8	38
103	Key players of neuroendocrine differentiation in prostate cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S112-S112.	0.7	1
104	Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 572-572.	0.7	28
105	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. <i>Current Drug Metabolism</i> , 2019, 20, 305-312.	0.7	11
106	Optimizing renal function and outcome of patients with cT2 renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S39-S39.	0.7	0
107	RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15663-e15663.	0.8	0
108	Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. <i>Annals of Translational Medicine</i> , 2019, 7, S194-S194.	0.7	1

#	ARTICLE	IF	CITATIONS
109	Association among metabolic syndrome, inflammation, and survival in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e1-240.e11.	0.8	20
110	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2018, 64, 11-20.	3.4	76
111	Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1869, 78-84.	3.3	150
112	High CTLA-4 expression correlates with poor prognosis in thymoma patients. <i>Oncotarget</i> , 2018, 9, 16665-16677.	0.8	24
113	Quick steps toward precision medicine in renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 283-285.	0.4	0
114	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2018, 10, 1303-1313.	1.0	3
115	The Identification of Immunological Biomarkers in Kidney Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 456.	1.3	40
116	Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?. <i>Future Oncology</i> , 2018, 14, 2997-2999.	1.1	7
117	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 397.	1.3	20
118	Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 5773-5782.	0.5	17
119	Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. <i>Drugs in Context</i> , 2018, 7, 1-8.	1.0	63
120	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 1-6.	2.0	10
121	Tivozanib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1021-1025.	0.9	16
122	â€œImmuno-Transient Receptor Potential Ion Channelsâ€: The Role in Monocyte- and Macrophage-Mediated Inflammatory Responses. <i>Frontiers in Immunology</i> , 2018, 9, 1273.	2.2	56
123	Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 221.	1.3	24
124	Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2018, 13, e0197035.	1.1	20
125	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018, 14, 2559-2564.	1.1	6
126	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , 2018, 68, 80-85.	3.4	27



#	ARTICLE	IF	CITATIONS
127	Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. <i>European Urology</i> , 2018, 74, 521-522.	0.9	41
128	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 645-655.	1.5	20
129	Editorial on "Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial". <i>Translational Cancer Research</i> , 2018, 7, S74-S76.	0.4	0
130	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. <i>World Journal of Urology</i> , 2017, 35, 517-526.	1.2	16
131	First-Line Pazopanib in Non-clear-cell Renal carcinoma: The Italian Retrospective Multicenter PANORAMA Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e609-e614.	0.9	42
132	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 541.e7-541.e13.	0.8	10
133	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. <i>European Urology Supplements</i> , 2017, 16, 301-308.	0.1	6
134	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. <i>Oncology</i> , 2017, 92, 269-275.	0.9	5
135	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. <i>European Urology Supplements</i> , 2017, 16, 309-315.	0.1	10
136	Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035). <i>Cancer Treatment Reviews</i> , 2017, 60, 12-17.	3.4	15
137	Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 123-131.	3.4	49
138	Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. <i>Oncotarget</i> , 2017, 8, 23871-23879.	0.8	36
139	Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. <i>Frontiers in Oncology</i> , 2017, 7, 305.	1.3	20
140	Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner. <i>Oncotarget</i> , 2017, 8, 3380-3395.	0.8	29
141	The TRPV1 ion channel regulates thymocyte differentiation by modulating autophagy and proteasome activity. <i>Oncotarget</i> , 2017, 8, 90766-90780.	0.8	24
142	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2016, 17, 771-776.	1.0	20
143	Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors). <i>Current Drug Targets</i> , 2016, 17, 748-749.	1.0	4
144	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , 2016, 7, 54564-54571.	0.8	116

#	ARTICLE	IF	CITATIONS
145	Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. PLoS ONE, 2016, 11, e0152079.	1.1	38
146	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. PLoS ONE, 2016, 11, e0151662.	1.1	56
147	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. BioDrugs, 2016, 30, 263-273.	2.2	22
148	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3. European Urology, 2016, 70, e69-e70.	0.9	0
149	Handling of the Surgical Specimen and Pathology Reporting of Penile Neoplasms. , 2016, , 275-280.		0
150	Handling of the Surgical Specimen and Pathology Reporting of Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis. , 2016, , 165-170.		0
151	Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: "Game Over"? Targeted Oncology, 2016, 11, 431-446.	1.7	7
152	Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. Cancer Treatment Reviews, 2016, 48, 20-24.	3.4	118
153	Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. Clinical Genitourinary Cancer, 2016, 14, 426-431.	0.9	9
154	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. Archives of Pathology and Laboratory Medicine, 2016, 140, 501-502.	1.2	11
155	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. Targeted Oncology, 2016, 11, 143-148.	1.7	152
156	Transplantation of kidneys with tumors. Journal of Nephrology, 2016, 29, 163-168.	0.9	9
157	Prostate cancer: from Gleason scoring to prognostic grade grouping. Expert Review of Anticancer Therapy, 2016, 16, 433-440.	1.1	26
158	Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. Critical Reviews in Oncology/Hematology, 2016, 99, 324-331.	2.0	11
159	Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. Molecular Diagnosis and Therapy, 2016, 20, 111-117.	1.6	77
160	Metabolic phenotype of bladder cancer. Cancer Treatment Reviews, 2016, 45, 46-57.	3.4	201
161	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4. European Urology, 2016, 70, e72-e74.	0.9	6
162	Hyponatremia in cancer patients: Time for a new approach. Critical Reviews in Oncology/Hematology, 2016, 102, 15-25.	2.0	50

#	ARTICLE	IF	CITATIONS
163	AR-V7 and prostate cancer: The watershed for treatment selection?. <i>Cancer Treatment Reviews</i> , 2016, 43, 27-35.	3.4	49
164	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. <i>European Urology</i> , 2016, 69, 186-190.	0.9	18
165	Capsaicin triggers autophagic cell survival which drives epithelial mesenchymal transition and chemoresistance in bladder cancer cells in an Hedgehog-dependent manner. <i>Oncotarget</i> , 2016, 7, 50180-50194.	0.8	51
166	Post-transcriptional regulation of 5'-untranslated regions of human Transient Receptor Potential Vanilloid type-1 (TRPV-1) channels: role in the survival of glioma patients. <i>Oncotarget</i> , 2016, 7, 81541-81554.	0.8	15
167	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 33381-33390.	0.8	11
168	Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. <i>Oncotarget</i> , 2016, 7, 26916-26924.	0.8	44
169	Overexpression of transient receptor potential mucolipin-2 ion channels in gliomas: role in tumor growth and progression. <i>Oncotarget</i> , 2016, 7, 43654-43668.	0.8	48
170	Metabolic Alterations in Renal and Prostate Cancer. <i>Current Drug Metabolism</i> , 2016, 17, 150-155.	0.7	19
171	An Overview of Emerging Immunotargets of Genitourinary Tumors. <i>Current Drug Targets</i> , 2016, 17, 750-756.	1.0	13
172	Emerging Immunotargets in Bladder Cancer. <i>Current Drug Targets</i> , 2016, 17, 757-770.	1.0	9
173	Emerging Immunotargets and Immunotherapies in Prostate Cancer. <i>Current Drug Targets</i> , 2016, 17, 777-782.	1.0	10
174	mTOR Pathway in Renal Cell Carcinoma. , 2016, , 417-428.		0
175	Re: Epithelial-to-mesenchymal Transition in Renal Neoplasms. <i>European Urology</i> , 2015, 68, 736-737.	0.9	10
176	Danger- and pathogen-associated molecular patterns recognition by pattern-recognition receptors and ion channels of the transient receptor potential family triggers the inflammasome activation in immune cells and sensory neurons. <i>Journal of Neuroinflammation</i> , 2015, 12, 21.	3.1	126
177	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. <i>Future Oncology</i> , 2015, 11, 3159-3166.	1.1	10
178	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2015, 75, 1329-1338.	1.2	24
179	HER family Receptor Expression and Prognosis in Pancreatic Cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 327-332.	0.7	9
180	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2015, 9, 263.	0.3	6

#	ARTICLE	IF	CITATIONS
181	Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. <i>Oncotarget</i> , 2015, 6, 36245-36259.	0.8	46
182	Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies) <i>TJ ETQq0 0 0 rgt /Overlock 10 Tf</i>	1.0	1
183	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2015, 41, 614-622.	3.4	19
184	<i>Lgr5</i> expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses. <i>Future Oncology</i> , 2015, 11, 1037-1045.	1.1	10
185	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 303-309.	0.8	16
186	Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 81-90.	2.0	64
187	Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , 2015, 11, 1381-1388.	1.1	10
188	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1367-1369.	1.1	23
189	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , 2015, 1, FSO15.	0.9	58
190	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 206-219.	2.0	22
191	Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature. <i>Current Urology Reports</i> , 2015, 16, 3.	1.0	12
192	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 1905-1910.	0.2	11
193	The route to personalized medicine in bladder cancer: where do we stand?. <i>Targeted Oncology</i> , 2015, 10, 325-336.	1.7	14
194	PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. <i>Cancer Treatment Reviews</i> , 2015, 41, 114-121.	3.4	161
195	Chromium Exposure and Germinal Embryonal Carcinoma: First Two Cases and Review of the Literature. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2015, 78, 1-6.	1.1	17
196	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	3.5	65
197	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	0.7	72
198	Renal cancer in kidney transplanted patients. <i>Journal of Nephrology</i> , 2015, 28, 659-668.	0.9	38

#	ARTICLE	IF	CITATIONS
199	Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. <i>Human Pathology</i> , 2015, 46, 1040-1044.	1.1	7
200	<i>BAP1</i> , <i>PBRM1</i> and <i>SETD2</i> in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1201-1210.	1.5	78
201	Metabolic alterations in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 767-776.	3.4	71
202	<i>KRAS</i> mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma. <i>Future Oncology</i> , 2015, 11, 1905-1917.	1.1	11
203	The immun checkpoints in modern oncology: the next 15 years. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 917-921.	1.4	24
204	Emerging drugs for the treatment of bone metastasis. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 637-651.	1.0	5
205	Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target. <i>Cancer Treatment Reviews</i> , 2015, 41, 569-576.	3.4	41
206	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	1.7	49
207	High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1377-1384.	0.7	80
208	Cannabidiol stimulates $\Delta$ Ca <sup>2+</sup> -dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. <i>International Journal of Cancer</i> , 2015, 137, 1855-1869.	2.3	123
209	Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 195.	1.1	101
210	Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 113.e1-113.e7.	0.8	15
211	Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 809-824.	1.9	43
212	Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. <i>Future Oncology</i> , 2015, 11, 107-119.	1.1	16
213	Altering macrophage polarization in the tumor environment: the role of response gene to complement 32. <i>Cellular and Molecular Immunology</i> , 2015, 12, 783-784.	4.8	9
214	Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients. <i>Cellular and Molecular Immunology</i> , 2015, 12, 122-124.	4.8	2
215	Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Grønberg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. <i>Eur Urol</i> 2015;67:819-22. <i>European Urology</i> , 2015, 68, e134-e135.	0.9	4
216	Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 137-141.	0.9	28

#	ARTICLE	IF	CITATIONS
217	Conditional Survival of Patients Treated With First-Line Chemotherapy for Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 244-249.	0.9	10
218	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 765-773.	2.7	30
219	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.2	58
220	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015, 136, 1-10.	2.3	47
221	Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15594-e15594.	0.8	1
222	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. <i>PLoS ONE</i> , 2015, 10, e0120427.	1.1	9
223	Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells.. <i>Oncoscience</i> , 2015, 2, 395-409.	0.9	25
224	Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy. <i>Oncotarget</i> , 2015, 6, 19305-19315.	0.8	18
225	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. <i>Oncotarget</i> , 2015, 6, 32161-32168.	0.8	28
226	Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview. <i>Current Drug Targets</i> , 2015, 16, 96-102.	1.0	11
227	Bladder Cancer: Molecular Determinants of Personalized Therapy. <i>Current Drug Targets</i> , 2015, 16, 115-124.	1.0	18
228	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	1.1	33
229	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. <i>Canadian Urological Association Journal</i> , 2014, 8, 121.	0.3	8
230	Cross-talk between alpha1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation. <i>BMC Cancer</i> , 2014, 14, 921.	1.1	35
231	Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-9.	0.7	31
232	CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	51
233	Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 208-217.	2.0	29
234	Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR&#x2013;TKIs and mTOR inhibitor. <i>International Journal of Cancer</i> , 2014, 134, 2772-2777.	2.3	57

#	ARTICLE	IF	CITATIONS
235	Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?. <i>Diagnostic Pathology</i> , 2014, 9, 190.	0.9	10
236	Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. <i>Pathology</i> , 2014, 46, 653-655.	0.3	13
237	Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression. <i>Cells</i> , 2014, 3, 112-128.	1.8	48
238	[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas. <i>ISRN Oncology</i> , 2014, 2014, 1-6.	2.1	10
239	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 321-331.	2.7	27
240	Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review. <i>Cancer Treatment Reviews</i> , 2014, 40, 495-506.	3.4	15
241	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2014, 135, 763-773.	2.3	43
242	The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type 2. <i>International Journal of Cancer</i> , 2014, 134, 2534-2546.	2.3	86
243	Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 271-275.	3.4	84
244	Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 221-231.	3.3	46
245	Resiniferatoxin induces death of bladder cancer cells associated with mitochondrial dysfunction and reduces tumor growth in a xenograft mouse model. <i>Chemico-Biological Interactions</i> , 2014, 224, 128-135.	1.7	12
246	Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 630-637.	3.3	38
247	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 929-938.	1.1	65
248	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 471-471.	0.8	8
249	Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression. <i>Current Protein and Peptide Science</i> , 2014, 15, 732-737.	0.7	26
250	Expression and Function of the Transient Receptor Potential Ion Channel Family in the Hematologic Malignancies. <i>Current Molecular Pharmacology</i> , 2014, 6, 137-148.	0.7	25
251	Epigenetic, Genetic, and Acquired Regulation of Cav3 T-Type Calcium Channel Expression and Function in Tumor Growth and Progression. , 2014, , 277-295.		0
252	Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 113, 397-401.	1.4	17

#	ARTICLE	IF	CITATIONS
253	Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1757-1768.	2.0	110
254	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. <i>European Journal of Cancer</i> , 2013, 49, 2134-2142.	1.3	60
255	Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 697-709.	1.1	12
256	Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	35
257	The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses. <i>Frontiers in Immunology</i> , 2013, 4, 34.	2.2	77
258	Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. <i>Carcinogenesis</i> , 2013, 34, 48-57.	1.3	201
259	Oncogenic and Anti-Oncogenic Effects of Transient Receptor Potential Channels. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 344-366.	1.0	33
260	TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 274-293.	0.8	34
261	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 563.	1.0	22
262	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	1.1	66
263	Essential Role of Gli Proteins in Glioblastoma Multiforme. <i>Current Protein and Peptide Science</i> , 2013, 14, 133-140.	0.7	53
264	Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?. <i>Current Cancer Drug Targets</i> , 2013, 13, 313-325.	0.8	8
265	VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. <i>Anticancer Research</i> , 2013, 33, 5017-22.	0.5	12
266	Present and Future of Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: Analysis of Hematologic Toxicity. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2012, 7, 104-110.	0.5	20
267	Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder. <i>Advances in Urology</i> , 2012, 2012, 1-5.	0.6	22
268	Functional role of T-type calcium channels in tumour growth and progression: prospective in cancer therapy. <i>British Journal of Pharmacology</i> , 2012, 166, 1244-1246.	2.7	51
269	A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy. <i>Journal of Translational Medicine</i> , 2012, 10, 90.	1.8	12
270	Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. <i>Oncology Letters</i> , 2012, 4, 799-801.	0.8	10



#	ARTICLE	IF	CITATIONS
271	The transient receptor potential vanilloid $\alpha$ 2 cation channel impairs glioblastoma stem $\alpha$ like cell proliferation and promotes differentiation. <i>International Journal of Cancer</i> , 2012, 131, E1067-77.	2.3	71
272	Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. <i>Current Perspectives and Novel Strategies. Recent Patents on Biomarkers</i> , 2012, 2, 99-106.	0.3	1
273	Capsaicin promotes a more aggressive gene expression phenotype and invasiveness in null-TRPV1 urothelial cancer cells. <i>Carcinogenesis</i> , 2011, 32, 686-694.	1.3	58
274	New deals on the transcriptional and post-transcriptional regulation of TRP channel target genes during the angiogenesis of glioma. <i>Journal of Experimental and Integrative Medicine</i> , 2011, 1, 221.	0.1	6
275	TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. <i>Carcinogenesis</i> , 2010, 31, 794-803.	1.3	101
276	New Insight on the Role of Transient Receptor Potential (TRP) Channels in Driven Gliomagenesis Pathways. , 0, , .		1